{"schema_version":"1.0","type":"article","title":"拒絕被併購的 RevMed：Biotech 的獨立時代","url":"https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.md","lang":"zh-Hant","date":"2026-07-03","publish_at":"2026-07-03T01:18:26.381Z","updated_at":"2026-07-03","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資","製藥巨頭"],"summary":"圍繞 Revolution Medicines（RevMed）的併購傳聞，一直沒有真正停過。","key_points":[],"facts":[],"sections":["01｜RevMed 為什麼不急著賣？","02｜Daraxonrasib 是 RevMed 的獨立門票","03｜RevMed 想做的，不只是賣一個藥，而是建立 RAS franchise","04｜Biotech 的獨立時代，為什麼現在更可能發生？","05｜RevMed 和過去 Biotech 不同：它有「可複用」的第一張牌","06｜但獨立不是浪漫故事，RevMed 仍有三場硬仗","07｜台灣可以怎麼看？不是每家公司都該獨立，但藥華藥、逸達、台新藥各有啟示","結語｜RevMed 拒絕被買，背後是 Biotech 角色的改變"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":"https://www.ft.com/content/3b1e5908-1cf4-4cc8-ade2-f0636a90739c"},{"title":"[2]:","source":"","date":"","url":"https://www.royaltypharma.com/"},{"title":"[3]:","source":"","date":"","url":"https://www.investors.com/news/technology/revolution-medicines-stock-pancreatic-cancer-treatment/"},{"title":"[4]:","source":"","date":"","url":"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-rare-blood-disease"},{"title":"[5]:","source":"","date":"","url":"https://www.foreseepharma.com/"},{"title":"所有心情：","source":"","date":"","url":""},{"title":"4次分享","source":"","date":"","url":""}],"images":[{"alt":"Facebook 原圖：拒絕被併購的 RevMed：Biotech 的獨立時代（圖 1）","url":"https://drugnews.com.tw/assets/articles/revmed-biotech/facebook-01.png"},{"alt":"Facebook 原圖：拒絕被併購的 RevMed：Biotech 的獨立時代（圖 2）","url":"https://drugnews.com.tw/assets/articles/revmed-biotech/facebook-02.png"},{"alt":"Facebook 原圖：拒絕被併購的 RevMed：Biotech 的獨立時代（圖 3）","url":"https://drugnews.com.tw/assets/articles/revmed-biotech/facebook-03.png"},{"alt":"Facebook 原圖：拒絕被併購的 RevMed：Biotech 的獨立時代（圖 4）","url":"https://drugnews.com.tw/assets/articles/revmed-biotech/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/revmed-biotech/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-03）。拒絕被併購的 RevMed：Biotech 的獨立時代。https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-03-revmed-biotech-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}